Cross-posted from Pfizer's Think Science Now
Today Pfizer along with other major pharmaceutical researchers announced a unique data sharing agreement for Alzheimer’s Disease (press release here, and media coverage here). This is another exciting example of collaboration among pharmaceutical companies to advance science and address unmet medical need.
Data from over 4,000 Alzheimer’s patients that participated in 11 industry-sponsored trials will be made available to researchers around the world (patient identifiers are removed to protect individual privacy). Each company will also use common data standards from CDISC to ease data sharing (a step that will also improve FDA review time).
Is this the beginning of a new era of collaboration to make progress against some of the toughest diseases?